NovoCure Limited (NVCR)

JE — Healthcare Sector
Peers:   GMED  PODD  INSP  NARI  TMDX  INMD  ITGR  CNMD  LIVN  IRTC  HSKA  SWAV  PEN  MASI 

Automate Your Wheel Strategy on NVCR

With Tiblio's Option Bot, you can configure your own wheel strategy including NVCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NVCR
  • Rev/Share 5.6375
  • Book/Share 3.2821
  • PB 5.9108
  • Debt/Equity 1.9249
  • CurrentRatio 1.4655
  • ROIC -0.1983

 

  • MktCap 2162828400.0
  • FreeCF/Share -0.6542
  • PFCF -29.9802
  • PE -13.0308
  • Debt/Assets 0.5579
  • DivYield 0
  • ROE -0.4546

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade NVCR H.C. Wainwright Neutral Buy $24 $30 Oct. 16, 2024

News

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
NVCR
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for NovoCure (NVCR) points to a 105.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
Why NovoCure Stock Skyrocketed This Week
NVCR
Published: April 25, 2025 by: The Motley Fool
Sentiment: Positive

Shares of NovoCure (NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m.

Read More
image for news Why NovoCure Stock Skyrocketed This Week
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
NVCR
Published: April 24, 2025 by: Benzinga
Sentiment: Negative

NovoCure Ltd NVCR reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents.

Read More
image for news NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
NVCR
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive

The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More
image for news NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
NovoCure Surpasses Q1 Expectations
NVCR
Published: April 24, 2025 by: The Motley Fool
Sentiment: Positive

NovoCure (NVCR 7.15%), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street's estimate of $146 million.

Read More
image for news NovoCure Surpasses Q1 Expectations
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NVCR
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Negative

NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.36 per share a year ago.

Read More
image for news NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
NVCR
Published: March 04, 2025 by: The Motley Fool
Sentiment: Positive

Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

Read More
image for news Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth
NVCR
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive

NovoCure's stock has risen 42% since my October recommendation, but revenue diversification outside of glioblastoma (GBM) remains a concern. Despite FDA approvals, TTFields therapy faces adoption challenges due to marginal survival benefits and high costs, impacting market growth. NovoCure's financial health shows sufficient liquidity short-term, but profit margins will compress and S&M costs will rise in 2025.

Read More
image for news NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth
NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say
NVCR
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for NovoCure (NVCR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say

About NovoCure Limited (NVCR)

  • IPO Date 2015-10-01
  • Website https://www.novocure.com
  • Industry Medical - Instruments & Supplies
  • CEO Ms. Ashley Cordova
  • Employees 1488

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.